| Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Texas Heart Institute designates this educational activity for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Estimated Study Time
The estimated time to complete this activity, including review of the materials and completion of the course assessment is 30 minutes. Repurposing Statement
If you previously completed and received credit for the live CME-sponsored grand rounds entitled, DVT and Pulmonary Embolism, on August 1, 2008, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will the Texas Heart Institute award, duplicate credit for the activity. Term of Approval
August 18, 2008 through August 18, 2011. Continuation of CME credit from August 18, 2011 depends on a thorough review of the content for currency and accuracy. Peer Review
In August 2008, this continuing medical education activity was reviewed for currency and accuracy of content by Patrick J. Hogan, MD, FACC, Director, Learning Resource Center and Co-Chairman, Medical Education Committee—Texas Heart Institute, Houston, Texas. Disclosure of Relationships
It is the intent of the Texas Heart Institute to ensure that its educational mission and its continuing medical activities in particular, should not be influenced by the special interests of individuals associated with its program. Faculty Disclosure
In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, faculty members have disclosed their relationships, either with one or more of the manufacturers of commercial products discussed, or with one or more of the corporate organizations offering educational grants for the live continuing medical education activity. Dr. Muntz discloses the following, relevant to this program: Consultant/Honoraria—DuPont and AstraZeneca; Speaker’s Bureau—sanofi aventis, GlaxoSmithKline, and DuPont; Research Trial—Daiichi Sankyo, Co., Ltd.; Principal Investigator—Bristol-Myers Squibb. | 
